Thomas J. DesRosier
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Thomas J. DesRosier
Thomas J. DesRosier is recorded as CEO at Seres Therapeutics, Inc. (MCRB). Seres Therapeutics, Inc. reported in an 8-K filed March 2, 2026 that Thomas J. DesRosier was terminated as Co-President and Co-Chief Executive Officer, effective March 2, 2026. Seres Therapeutics, Inc. reported in an 8-K filed July 22, 2025 that Thomas J. DesRosier was appointed Co-Chief Executive Officer and Co-President, effective August 1, 2025. The proxy statement of Seres Therapeutics, Inc. reports total compensation of $1,136,023 for Thomas J. DesRosier in fiscal 2025, including a base salary of $512,900. Disclosed compensation is on record for 5 fiscal years. Thomas J. DesRosier has spoken on 1 earnings call across 1 company, most recently for Seres Therapeutics, Inc. on August 6, 2025.
“As a result of the appointment of Mr. Kender as Interim Chief Executive Officer, Thomas J. DesRosier and Marella Thorell ceased serving as Co-Presidents and Co-Chief Executive Officers of the Company as of the Effective Date.”
“On July 17, 2025, the Company's Executive Vice President and Chief Financial Officer, Marella Thorell, and the Company's Executive Vice President and Chief Legal Officer, Thomas J. DesRosier, were appointed as the Co-Chief Executive Officers and Co-Presidents of the Company and designated as the Company's co-principal executive officers, in each case effective as of August 1, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
-
Seres Therapeutics, Inc. (MCRB)
Proxy statement
CurrentStart not stated–present
-
Seres Therapeutics, Inc. (MCRB)
Proxy statement
Start not stated–2026-03-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Seres Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Marella Thorell CEO, CFO, Chief Accounting Officer
- Richard N. Kender CEO, Chairman, Board Member
- Roger J. Pomerantz CEO
- Kelly Brady COO
- Kelly Brady, M.S. COO
- David S. Ege CTO
- David Arkowitz Chief Accounting Officer
- Eric Shaff Chief Accounting Officer
- Claire Fraser, Ph.D. Board Member
- Claire M. Fraser, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Seres Therapeutics, Inc. (MCRB) | Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer | $512,900 | $1,136,023 |
| 2024 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President and Chief Legal Officer | $498,000 | $1,248,507 |
| 2020 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President, Chief Legal Officer and Secretary | $450,000 | $1,437,260 |
| 2019 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President, Chief Legal Officer and Secretary | $428,300 | $977,341 |
| 2018 | Seres Therapeutics, Inc. (MCRB) | Chief Legal Officer, Executive Vice President, and Secretary | $413,800 | $1,839,330 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.